Publisher
Springer Nature Singapore
Reference5 articles.
1. Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3494.
2. Gotoh A, Ohyashiki K, Oshimi K, et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “lung injury by bortezomib” joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol. 2006;84:406–12.
3. Yoshizawa K, Mukai HY, Miyazawa M, et al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105:195–201.
4. Mukai H, Oyashiki K, Kato T, et al. The appearance of lung injuries associated with treatment of bortezomib in Japanese people. Clin Blood. 2011;52:1859–69.
5. Velcade injection 3 mg. The results of interim aggregation (The aggregated results using 2 cycle data in 500 cases). Janssen Pharmaceutical K.K.